user

FGF-23 protein is present in normal plasma and is increased in patients with tumor-induced osteomalacia.

被引：0
|
作者：
Yamazaki, Y
Shibata, M
Okazaki, R
Takeuchi, Y
Fujita, T
Yamashita, T
Fukumoto, S
机构：
[1] Kirin Brewery Co Ltd, Pharmaceut Res Labs, Takasaki, Gumma, Japan
[2] Teikyo Univ, Dept Med, Ichihara, Japan
[3] Univ Tokyo, Sch Med, Dept Med, Tokyo 113, Japan
[4] Tokyo Univ Hosp, Dept Lab Med, Tokyo 113, Japan
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2002年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1143
引用
收藏
页码：S159 / S159
页数：1
相关论文
共 50 条
  • [21] Rapid detection of intact FGF-23 in tumor tissue from patients with oncogenic osteomalacia
    Mannstadt, Michael
    Lorente, Carol
    Jueppner, Harald
    CLINICAL CHEMISTRY, 2008, 54 (07) : 1252 - 1254
  • [22] TUMOR-INDUCED OSTEOMALACIA. A CASE SERIES FROM MEDIUM INCOME COUNTRY
    Prieto-Saldarriaga, C.
    Gutierrez-Restrepo, J.
    Contreras, D.
    Varela-Aguirre, G.
    Roman-Gonzalez, A.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 35 : S225 - S225
  • [23] BUROSUMAB (ANTI-FGF23 MONOCLONAL ANTIBODY) IN THE TREATMENT OF A PATIENT WITH RECURRENT TUMOR INDUCED OSTEOMALACIA.
    Crotti, C.
    Zucchi, F.
    Messa, P.
    Caporali, R.
    Varenna, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1758 - 1758
  • [24] Immunohistochemical detection of FGF-23 protein in tumors that cause oncogenic osteomalacia
    Larsson, T
    Zahradnik, R
    Lavigne, J
    Ljunggren, Ö
    Jüppner, H
    Jonsson, KB
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2003, 148 (02) : 269 - 276
  • [25] Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer
    Abramson, Matthew
    Glezerman, Ilya G.
    Srinivasan, Maya
    Ross, Richard
    Flombaum, Carlos
    Gutgarts, Victoria
    CLINICAL NEPHROLOGY, 2021, 95 (02) : 104 - 111
  • [26] FGF-23 transmitted tumor - induced hypophosphatemic osteomalacia: a rare case of a young woman with recurrent fractures
    Frank, Florian
    Gerber, Lukas
    Cornelius, Alexander
    Baumhoer, Daniel
    Krieg, Andreas
    SWISS MEDICAL WEEKLY, 2022, 152 : 65S - 65S
  • [27] Tumor-induced osteomalacia with normal systemic fibroblast growth factor-23 level
    Amblee, Ambika
    Uy, Juanito
    Senseng, Carmencita
    Hart, Peter
    CLINICAL KIDNEY JOURNAL, 2014, 7 (02): : 186 - 189
  • [28] Tumor-Induced Osteomalacia: Treatment Progress Using Burosumab, an Anti-FGF23 Monoclonal Antibody
    Whyte, Michael P.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2021, 36 (04) : 625 - 626
  • [29] Infigratinib Reduces Fibroblast Growth Factor 23 (FGF23) and Increases Blood Phosphate in Tumor-Induced Osteomalacia
    Hartley, Iris R.
    Roszko, Kelly L.
    Li, Xiaobai
    Pozo, Karen
    Streit, Jamie
    del Rivero, Jaydira
    Magone, M. Teresa
    Smith, Michaele R.
    Vold, Roo
    Dambkowski, Carl L.
    Collins, Michael T.
    Gafni, Rachel, I
    JBMR PLUS, 2022, 6 (08)
  • [30] Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia
    Yamazaki, Y
    Okazaki, R
    Shibata, M
    Hasegawa, Y
    Satoh, K
    Tajima, T
    Takeuchi, Y
    Fujita, T
    Nakahara, K
    Yamashita, T
    Fukumoto, S
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (11): : 4957 - 4960
12345